2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4033 K36-MMSET-001 part B (dose expansion phase): A phase 1 study of gintemetostat (KTX-1001), an oral, first-in-class, selective, and potent MMSET catalytic inhibitor that suppresses H3K36me2 in patients with relapsed and refractory multiple myeloma

Edward A. Stadtmauer, MD, Saad Z. Usmani, MD2, Pierre Bories, MD3, David Dingli, MD, PhD4, Salomon Manier, MD, PhD5, Jesús G. Berdeja, MD6, Paula Rodriguez Otero, MD, PhD7, Andrew J. Yee, MD8, Xavier Leleu Sr, MD, PhD9, Joaquin Martinez-Lopez Sr, MD, PhD10, Sikander Ailawadhi, MD11, Cristina Gasparetto, MD12, Sagar Lonial, MD, FACP13, Alfred Chung, MD14, David S Siegel, MD, PhD15, Cyrille Touzeau Sr, MD, PhD16, Aimaz Afrough, MD17, Cindy Varga, MD,BSc18, Laura Rosiñol Dachs Sr, MD, PhD19, Suzanne Trudel, MD20, Yuxin Liu, MD21, Miriam Barnett22, Shinta Cheng, MD, PhD23, Andrea Viqueira, MD24, Maria-Victoria Mateos Jr, MD, PhD25
1 University of Pennsylvania Abramson Cancer Center, Philadelphia, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Early phase unit, Oncopole Claudius Regaud, IUCT - Oncopole, Toulouse, France
4 Mayo Clinic, Rochester, United States
5 Hôpital Universitaire de Lille, Lille, France
6 GHCR Tennessee Oncology, Nashville, United States
7 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
8 Massachusetts General Hospital Cancer Center, Boston, United States
9 Centre Hospitalier Universitaire de Poitiers, Poitiers, France
10 Hospital Universitario 12 de Octubre, Madrid, Spain
11 Mayo Clinic, Jacksonville, United States
12 Duke University Medical Center, Durham, United States
13 Winship Cancer Institute, Emory University Hospital, Atlanta, United States
14 University of California San Francisco, San Francisco, United States
15 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, United States
16 Hôpital Universitaire de Nantes, Nantes, France
17 University of Texas Southwestern Medical Center, Dallas, United States
18 Levine Cancer Institute, Atrium Health/Wake Forest Baptists, Charlotte, United States
19 IDIBAPS, Hospital Clinic, Barcelona, Spain
20 Princess Margaret Cancer Centre, Toronto, Canada
21 Dana-Farber Cancer Institute, Boston, United States
22 K36 Therapeutics, Cambridge, United States
23 K36 Therapeutics, Cambridge, United States
24 Independent Consultant, Madrid, Spain
25 University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain

Background and Significance: Despite recent significant advances, multiple myeloma (MM) remains incurable and new therapies are needed to improve outcomes, especially in patients with poor prognosis characteristics. The t(4;14) translocation results in overexpression of the histone lysine methyl transferase multiple myeloma SET domain-containing protein (MMSET) and has been associated with poor clinical outcomes in patients with MM.

Gintemetostat (KTX-1001) is a first-in-class, orally available, small molecule, selective and potent inhibitor of MMSET, developed to directly target the high-risk t(4;14) translocation. Inhibition of MMSET prevents the dimethylation of histone H3 lysine 36 (H3K36me2), resulting in epigenetic reprogramming of malignant plasma cells and downregulation of oncogenic transcriptional programs. Preclinically, gintemetostat synergistically inhibited cell viability in MM cell lines when combined with proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), or cereblon E3 ligase modulators (CELMoDs). The dose-expansion phase (Part B) of the K36-MMSET-001 study aims to determine the preliminary efficacy as well as the safety, tolerability, and recommended phase 2 dose (RP2D) of gintemetostat in combination with other anti-myeloma therapies in patients with t(4;14) relapsed/refractory MM (RRMM).

The primary endpoint of the dose escalation phase (Part A) of the study was to determine the maximum tolerated dose and the recommended phase 2 dose (RP2D) of gintemetostat as monotherapy (Usmani, 2025). Based on the initial results from Part A, the safety review committee selected 2 recommended phase 2 doses (RP2D1 and RP2D2), to undergo further optimization in combination with other anti-myeloma therapies in the dose-expansion phase.

Study Design and Methods: K36-MMSET-001 (NCT05651932) is an ongoing, open-label, multinational phase 1 study investigating gintemetostat in patients with RRMM. The study includes 2 parts: a dose escalation phase (part A) to determine the RP2D of gintemetostat as monotherapy and a dose expansion phase (Part B) to assess the preliminary efficacy and safety of gintemetostat in combination with mezigdomide and dexamethasone or carfilzomib and dexamethasone or pomalidomide and dexamethasone.

Eligible patients are adults (≥18 years) with a diagnosis of RRMM per IMWG including at least 1 of the following: serum M-protein ≥0.5 g/dL, urine M-protein ≥200 mg/24 h, involved sFLC ≥10 mg/dL with an abnormal ratio, or bone marrow plasma cells ≥30% (if only criterion for measurability). Patients must have prior exposure to at least one IMiD, one PI, and one anti-CD38 antibody, and have received at least 1 and up to 3 prior lines of therapy in the carfilzomib and pomalidomide cohorts and at least 2 prior lines of therapy in the mezigdomide cohort. Patients must have a t(4;14) translocation as determined by an analytically validated Fluorescence In Situ Hybridization (FISH) assay performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory.

Part B will enroll up to 100 patients in the following combination dose cohorts (up to 20 per cohort):

Gintemetostat at the RP2D1 + mezigdomide + dexamethasone Gintemetostat at the RP2D2 + mezigdomide + dexamethasone Gintemetostat at the RP2D1 + carfilzomib + dexamethasone Gintemetostat at the RP2D2 + carfilzomib + dexamethasone Gintemetostat at the RP2D2 + pomalidomide + dexamethasone

Patients will be observed for dose-limiting toxicities (DLTs) during the first cycle.  All patients will receive treatment until disease progression, withdrawal of consent, lost to follow-up, unacceptable toxicity, or study termination.

The primary endpoint of Part B is to evaluate the preliminary efficacy and antitumor effects of gintemetostat combined with other anti-myeloma therapies. Secondary endpoints include defining the RP2D of gintemetostat when used with other anti-myeloma therapies, further characterizing the safety profile of gintemetostat administered at RP2D1 and RP2D2 with other anti-myeloma therapies. PK and PD effects of gintemetostat including H3K36me2 levels in surrogate or tumor tissues, will be analyzed as part of exploratory endpoints.

Edward A. Stadtmauer, MD: Astra Zeneca - Research Funding; K36 therapeutics - Research Funding; Bristol Myers Squibb - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)